Floatz Rating
C34/100
Confidence
Indicative
Sponsor
Bellicum Pharmaceuticals
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02477878CT.gov Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | — | Active Not Recruiting | — | — | — |
NCT02786485CT.gov Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | — | Withdrawn | — | — | — |
NCT01744223CT.gov Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivogenlecleucel (this asset) | Bellicum Pharmaceuticals | P1/2 | C · 34 |
| Vinblastine | Intensity Therapeutics, Inc. | P4 | BBB |
| Prednisolone | The Lymphoma Academic Research Organisation | P4 | BBB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P4 | BBB |
| Bleomycin | Shandong Provincial Hospital | P4 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Vincristine Sulfate | Inhye Ahn | P3 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BB |
| Methotrexate | University of Chicago | P4 | BB |
+42 more in the Lymphoma cohort
Other indications for Rivogenlecleucel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P2/3 | CC · 45 |
| Myelodysplastic Syndrome | — | P2/3 | CC · 41 |
| Inborn Error Of Immunity | — | P1/2 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivogenlecleucel in Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivogenlecleucel-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →